HSANZ Free Communications 4: DS/MPN/CML/Bone marrow failure
Tracks
HSANZ
| Monday, October 19, 2026 |
| 8:30 AM - 10:00 AM |
Speaker
Dr Jenny Yoon
Haematology Registrar
Te Whatu Ora Health NZ, Te Toka Tumai
Potential for treatment free remission in newly diagnosed chronic phase chronic myeloid leukaemia initially achieving major molecular response on dasatinib and then transitioned to imatinib. Results of the phase 2 kinase inhibition with sprycel startup (KISS) study
8:30 AM - 8:45 AM
Dr Ian Irving
Clinical Haematologist
Icon Cancer Centre
Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial
8:45 AM - 9:00 AM
Dr Shuh Ying Tan
Acute Leukaemia And Myeloid Diseases Service Lead
St Vincent's Institute of Medical Research
Update from phase 2 RESTORE trial of elritercept in patients with myelofibrosis receiving ruxolitinib
9:00 AM - 9:15 AM
Dr Ashish Bajel
Consultant Haematologist
Peter Maccallum Cancer Centre / The Royal Melbourne Hospital
Encore: Outcomes with momelotinib in patients with intermediate-1(int-1)– vs intermediate-2 (int-2)–/high-risk myelofibrosis (MF): post hoc analyses of the phase 3 SIMPLIFY-1 and MOMENTUM trials
9:15 AM - 9:30 AM
Ms Ruby Hamilton
PhD Student
The University Of Western Australia
Plasma cell-free DNA monitoring of myelofibrosis following allogeneic stem cell transplantation
9:30 AM - 9:45 AM
Dr Chloe Thompson-Peach
Post-Doctoral Fellow
Adelaide University
Dual-epitope targeting enables precision therapy for type 1 versus type 2 CALR-mutant MPN
9:45 AM - 10:00 AM
